Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to stop kidney rejection

NCT ID NCT07011238

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a type of immune cell called memory B cells in people waiting for a kidney transplant who have certain antibodies. Researchers want to understand why some of these cells cause rejection while others don't. They will analyze blood samples from 51 patients to find patterns that could improve transplant success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict and prevent kidney transplant rejection by identifying harmful immune cells.
What could go wrong
This is an early observational study with only 51 participants, so findings may not apply to all patients. It aims to gather knowledge, not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 51 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients awaiting kidney transplantation and carrying HLA antibodies following immunizing events

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Rouen University Hospital patient monitored in the Nephrology and Kidney Transplantation Department, registered on the national kidney transplant waiting list * Carrier of HLA antibodies, including at least anti-HLA2, identified during the last screening * Notion of classic immune-promoting events including at least one previous transplant or pregnancy, or absence of a known immune-promoting event (naïve patient group) * Incompatible graft rate (IGR) * IGR ≥ 85% (hyperimmunized patient group with anti-HLA polyreactivity) or * IGR between 50% and 85% (immunized patient group with a more restricted repertoire of HLA reactivities) or * IGR \< 50% (naïve patient group with no known history of immune-promoting events) * Person who has read and understood the information letter and does not object Not participating in the study * Affiliation to a social security scheme Exclusion Criteria: * Patients who have received rituximab in the previous year (B-cell depleting therapy) * Patients undergoing an HLA desensitization protocol using plasmapheresis and/or rituximab * Patients with an active infection * Persons deprived of their liberty by an administrative or judicial decision or persons placed under judicial protection/guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hopsital of Rouen

    RECRUITING

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.